SH3GL2 and ischemia: Treatment with Tat peptide or Control-SH3GL2 significantly increased the travel distance by more than 2.5-fold compared to that in the control group, and Tat-SH3GL2 treatment significantly ameliorated the increase in travel distance 1 day after ischemia.